Psoriasis
Conditions
Brief summary
The aim of this double blind comparative clinical study is to evaluate the efficacy of AHAs combined with nanocarriers and their use as a non steroidal alternative drug for long term management of plaque psoriasis
Interventions
DRUGAlpha Hydroxy Acids with nanocarriers
Topical Alpha Hydroxy Acids formulated with nanocarriers applied to psoriatic plaques.
DRUGAlpha Hydroxy Acids only.
Topical Alpha Hydroxy Acids only applied to psoriatic plaques.
Topical calcipotriol plus betamethasone ointment applied to psoriatic plaques.
OTHERPlacebo.
Vehicle control / Placebo topical application applied to psoriatic plaques
Sponsors
Al-Azhar University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
- Mid to moderate cases according to Psoriasis Area and Severity Index (PASI). * Age from18-65 years old. * Denovo psoriatic patients and patients with no psoriasis therapy in the previous two months.
Exclusion criteria
* Severe irritation and highly inflamed skin. * Pregnant and lactating females. * Patients with acute renal insufficiency. * Face, flexural and groin lesions.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Percentage Change in PASI Score. | Baseline and 8 weeks | Reduction in PASI score from baseline to week 8. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Dermatology Life Quality Index (DLQI) | Baseline and 8 weeks). | Changes in DLQI score to assess the impact of treatment on patients' quality of life. |
Countries
Egypt
Outcome results
None listed